Figure 6.
Anti–IGSF9-DXd treats the early and mid-stage AML models. About 1 × 106 MV4-11-luc cells are injected into NSG mice (n = 10). Treatment with anti-IGSF9 as a control and anti–IGSF9-DXd is initiated the following day and administered every 5 days thereafter. (A) Disease progression is monitored by bioluminescence imaging. (B) The GFP+ cell percentages in bone marrow, spleen and lungs are detected by flow cytometry, and (C) the tumors in all organs are shown by bioluminescence imaging. About 1 × 106 THP-1-luc cells are injected into NSG mice (n = 10), (D) and anti-IGSF9 or anti–IGSF9-DXd are administered on days 7 and 14, and (E) the survival curves are drawn.

Anti–IGSF9-DXd treats the early and mid-stage AML models. About 1 × 106 MV4-11-luc cells are injected into NSG mice (n = 10). Treatment with anti-IGSF9 as a control and anti–IGSF9-DXd is initiated the following day and administered every 5 days thereafter. (A) Disease progression is monitored by bioluminescence imaging. (B) The GFP+ cell percentages in bone marrow, spleen and lungs are detected by flow cytometry, and (C) the tumors in all organs are shown by bioluminescence imaging. About 1 × 106 THP-1-luc cells are injected into NSG mice (n = 10), (D) and anti-IGSF9 or anti–IGSF9-DXd are administered on days 7 and 14, and (E) the survival curves are drawn.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal